webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Duocarmycin MB

  CAS No.: 1613286-58-0   Cat No.: BADC-00609   Purity: ≥95% 4.5  

Duocarmycin MB is an antibody drug conjugate (ADC) toxin that can be used against multidrug resistant cell lines. Duocarmycin is a DNA alkylating agent that binds in minor groove.

Duocarmycin MB

Structure of 1613286-58-0

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C27H26ClN3O4
Molecular Weight
491.97
Shipping
Room temperature
Shipping
Store at -20°C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
Carbamic acid, N-[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-6-yl]-, 1,1-dimethylethyl ester; 1,1-Dimethylethyl N-[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-6-yl]carbamate; 2-Methyl-2-propanyl (2-{[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benzo[e]indol-3-yl]carbonyl}-1H-indol-6-yl)carbamate
IUPAC Name
tert-butyl N-[2-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indole-3-carbonyl]-1H-indol-6-yl]carbamate
Canonical SMILES
CC(C)(C)OC(=O)NC1=CC2=C(C=C1)C=C(N2)C(=O)N3CC(C4=C3C=C(C5=CC=CC=C54)O)CCl
InChI
InChI=1S/C27H26ClN3O4/c1-27(2,3)35-26(34)29-17-9-8-15-10-21(30-20(15)11-17)25(33)31-14-16(13-28)24-19-7-5-4-6-18(19)23(32)12-22(24)31/h4-12,16,30,32H,13-14H2,1-3H3,(H,29,34)/t16-/m1/s1
InChIKey
IVUIPHKZPNUXGG-MRXNPFEDSA-N
Density
1.4±0.1 g/cm3
Solubility
Soluble in DMSO
Shipping
Room temperature
Storage
Store at -20°C
Boiling Point
703.0±60.0°C at 760 mmHg
1.Duocarmycins--natures prodrugs?
Searcey M
The duocarmycins and (+)-CC-1065 are amongst the most potent antitumour antibiotics discovered to date and yet have not progressed into the clinic. The natural products are extremely stable to nucleophilic attack until bound to their DNA target and are not substrates for any other biological nucleophile. The mechanism for this target activation of the duocarmycins is discussed with relation to both an acid-catalyzed activation and a binding-induced conformational change leading to ground state destabilization. It is suggested that targeting of the duocarmycins to their site of action in a tumour may be more important than introducing systemically-activated prodrugs as the natural product itself can be considered to be a type of prodrug, activated only on binding to its targets. Methods that have been used to target CC-1065 and the duocarmycins are reviewed as well as efforts towards systemically activated prodrugs. A simple analysis of the approaches that could be taken to vary the structure for targeting is suggested.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: N3-L-Cit-OH | Cryptophycin 1 | Telomestatin | Paclitaxel D5 | Seco-Duocarmycin MB | Ungerine Nitrate | Galantamine hydrobromide | CBT-161 | Luteolin 7-O-glucoside | Seco-DuocarmycinDMG | Duocarmycin MB
Send Inquiry
Verification code
Inquiry Basket